Therapeutic targeting of regulatory T cells in cancer

The success of immunotherapy in oncology underscores the vital role of the immune system in cancer development. Regulatory T cells (Tregs) maintain a fine balance between autoimmunity and immune suppression. They have multi-ple roles in the tumor microenvironment (TME) but act particularly in suppressing T cell activation. This review focuses on the detrimental and sometimes benefi-cial roles of Tregs in tumors, our current understanding of recruitment and stabilization of Tregs within the TME, and current Treg-targeted therapeutics. Research identifying subpopulations of Tregs and their respective functions and interactions within the complex networks of the TME will be crucial to develop the next generation of immunotherapies. Through these advances, Treg-targeted immunotherapy could have important implications for the future of oncology.

Automated summary

The success of immunotherapy in oncology highlights the important role of the immune system in cancer development. Regulatory T cells (Tregs) play multiple roles in the tumor microenvironment, particularly in suppressing T cell activation. Understanding the subpopulations of Tregs and their functions within the complex networks of the tumor microenvironment is crucial for the development of next-generation immunotherapies.